Article Information
vol. 45 no. 5 1434-1445
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 23, 2014
- Accepted January 5, 2015
- Published online April 30, 2015.
Article Versions
- previous version (March 5, 2015 - 06:49).
- previous version (March 5, 2015 - 07:39).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©ERS 2015 ERJ Open articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Lutz Wollin1⇑,
- Eva Wex1,
- Alexander Pautsch1,
- Gisela Schnapp1,
- Katrin E. Hostettler2,
- Susanne Stowasser3 and
- Martin Kolb4
- 1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- 2University Hospital Basel, Basel, Switzerland
- 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
- 4McMaster University, Hamilton, ON, Canada
- Stefan-Lutz Wollin, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Strasse 65, 88397 Biberach, Germany. E-mail: Stefan-lutz.wollin{at}boehringer-ingelheim.com
Funding
Boehringer Ingelheim
Article usage
Altmetrics
Vol 45 Issue 5
Table of Contents
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Jump To
- Article
- Abstract
- Abstract
- Introduction
- Idiopathic pulmonary fibrosis
- PDGF/PDGFR signalling in pulmonary fibrosis
- FGF/FGFR signalling in pulmonary fibrosis
- VEGF/VEGFR signalling in pulmonary fibrosis
- Nintedanib is a potent inhibitor of the receptor tyrosine kinases PDGFR, FGFR and VEGFR
- Nintedanib interferes with essential fibrotic processes in a variety of in vitro assays and in vivo models
- Clinical efficacy
- Summary and conclusion
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics